What Pfizer Bulls Got Right

Pfizer spent 2026 stacking cancer headlines, from fresh breast cancer approvals to a multibillion dollar oncology alliance, even as quarterly profit swung from a US$2,885 million gain to a loss and net margin moved from 19.7% to 1.7% in the red. Investors who held Pfizer from the start of the year saw a 23.0% return, including dividends. If you were weighing a buy on 1 January, what needed to look credible about this reinvention story to take that risk? A Narrative on Simply Wall St is one...